Isomorphic Labs, an AI drug development company spun off from DeepMind, is negotiating about $5 billion in financing, with a valuation of about $50 billion.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.